Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Debt-to-assets

Debt-to-assets at other companies

Alkermes logo
AlkermesALKS
0.4×+0.3×
JAN
Janus Living JAN
0×-0.1×

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc. ’s reported figures.

total debt/total assets=0.4×

Based on the most recent quarter.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's debt-to-assets?
Indivior Pharmaceuticals, Inc. (INDV) reported debt-to-assets of 0.4× in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's debt-to-assets changed year-over-year?
Indivior Pharmaceuticals, Inc. 's debt-to-assets increased by 58.0% year-over-year, from 0.3× to 0.4×.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's debt-to-assets?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's debt-to-assets has grown at a 34.7% compound annual growth rate (CAGR), from 0.2× to 0.3×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.